(Q40340882)

19 September 2017

Neuroborreliosis - Diagnostics, treatment and course (English)

1 reference

19 September 2017

0 references

1 reference

R Dersch

1

1 reference

PubMed ID

28175945

19 September 2017

S Rauer

series ordinal

2

1 reference

PubMed ID

28175945

19 September 2017

language of work or name

German

0 references

publication date

7 February 2017

1 reference

19 September 2017

1 reference

19 September 2017

88

1 reference

19 September 2017

4

1 reference

19 September 2017

419-431

1 reference

https://scigraph.springernature.com/pub.10.1007/s00115-016-0263-1

19 September 2017

0 references

cites work

How can we prevent Lyme disease?

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Assessing the risk of human granulocytic anaplasmosis and lyme borreliosis after a tick bite in Bavaria, Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

[What primary prevention should be used to prevent Lyme disease?]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Pilot study assessing the effectiveness of factory-treated, long-lasting permethrin-impregnated clothing for the prevention of tick bites during occupational tick exposure in highly infested military training areas, Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Neuroborreliosis-associated cerebral vasculitis: long-term outcome and health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Microbiological and serological diagnosis of Lyme borreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Antibodies against Borrelia burgdorferi sensu lato among Adults, Germany, 2008-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Borrelia burgdorferi-specific intrathecal antibody production in neuroborreliosis: a follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Differentiation of reinfection from relapse in recurrent Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Cytokine CXCL13--a possible early CSF marker for neuroborreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis - a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Destructive chronic borrelia meningoencephalitis in a child untreated for 15 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Practice Parameter: Treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

The neurological complications of Borrelia burgdorferi in the New Forest area of Hampshire

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Evaluation of study patients with Lyme disease, 10-20-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Psychological correlates of fatigue in rheumatoid arthritis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

A systematic review of Borrelia burgdorferi morphologic variants does not support a role in chronic Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-016-0263-1

Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis

21 January 2018

1 reference

12 December 2020

[Neurologic forms of Lyme disease. 12 cases]

1 reference

12 December 2020

Foci of tick-borne diseases in southwest Germany

1 reference

12 December 2020

Bannwarth's syndrome and the enlarged neurological spectrum of arthropod-borne borreliosis

1 reference

12 December 2020

Incidence of Lyme borreliosis in the Würzburg region of Germany

1 reference

12 December 2020

Risk of Borrelia burgdorferi infection in western Switzerland following a tick bite

1 reference

12 December 2020

Intrathecal synthesis of specific antibodies in neuroborreliosis. Comparison of different ELISA techniques and calculation methods

1 reference

12 December 2020

Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.

1 reference

12 December 2020

Lyme disease: a multisystem infection that affects the nervous system

1 reference

12 December 2020

Variable CSF findings in early and late Lyme neuroborreliosis: a follow-up study in 47 patients

1 reference

12 December 2020

Treatment of Lyme borreliosis. Randomized comparison of doxycycline and penicillin G

1 reference

12 December 2020

1 reference

12 December 2020

The chemokine CXCL13 in acute neuroborreliosis

1 reference

12 December 2020

Chronic polyneuropathy and Lyme disease

1 reference

12 December 2020

Temporal study of immunoglobin M seroreactivity to Borrelia burgdorferi in patients treated for Lyme borreliosis.

1 reference

12 December 2020

Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease

1 reference

12 December 2020

10.1007/S00115-016-0263-1

Identifiers

DOI

1 reference

19 September 2017

1 reference

PubMed ID

28175945